MCID: PNC034
MIFTS: 59

Pancreas Disease

Categories: Gastrointestinal diseases, Endocrine diseases

Aliases & Classifications for Pancreas Disease

Summaries for Pancreas Disease

Disease Ontology : 12 An endocrine system disease that is located in the pancreas.

MalaCards based summary : Pancreas Disease, also known as abnormality of the pancreas, is related to endocrine pancreas disease and pancreatitis, and has symptoms including gastrointestinal gas, digestive system symptom and nausea and vomiting. An important gene associated with Pancreas Disease is INS (Insulin), and among its related pathways/superpathways are Peptide ligand-binding receptors and G alpha (s) signalling events. The drugs Pancrelipase and Dexmedetomidine have been mentioned in the context of this disorder. Affiliated tissues include the pancreas, pancreas and lung, and related phenotypes are homeostasis/metabolism and adipose tissue

Wikipedia : 72 The pancreas /ˈpæŋkriəs/ is a glandular organ in the digestive system and endocrine system of... more...

Related Diseases for Pancreas Disease

Diseases related to Pancreas Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 128)
# Related Disease Score Top Affiliating Genes
1 endocrine pancreas disease 31.7 ABCC8 DPP4 GCG IGF1 INS LEP
2 pancreatitis 29.9 CCK PRSS1 SCT SPINK1 SST
3 duodenal ulcer 29.9 CCK INS SCT SST
4 body mass index quantitative trait locus 11 29.0 CCK DPP4 GCG IGF1 INS LEP
5 pancreas, annular 10.7
6 pancreatic agenesis 10.7
7 bronchus adenoma 10.7 POMC SST
8 bronchial adenomas/carcinoids childhood 10.7 POMC SST
9 scleredema adultorum 10.6 INS POMC
10 type 1 diabetes mellitus 15 10.6 GCG INS
11 pancreatic islet cell tumors 10.6 INS SST
12 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 10.6 LEP POMC
13 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.6 IGF1 INS
14 postgastrectomy syndrome 10.6 INS SST
15 functional gastric disease 10.6 CCK SST TRPV1
16 postural hypotension 10.6 INS SST
17 pancreatic agenesis 1 10.6 SCT SPINK1
18 maturity-onset diabetes of the young, type 3 10.6 CELA3B INS
19 recurrent acute pancreatitis 10.6 PRSS1 SCT SPINK1
20 pain agnosia 10.6 CCK POMC TRPV1
21 pituitary-dependent cushing's disease 10.6 INS POMC SST
22 agnosia 10.6 CCK POMC TRPV1
23 dyspepsia 10.6 CCK SST TRPV1
24 female reproductive system disease 10.6 INS POMC TRPV1
25 stomach disease 10.6 CCK SST TRPV1
26 central nervous system germinoma 10.6 AVP POMC
27 sheehan syndrome 10.6 IGF1 INS POMC
28 gastrinoma 10.6 INS SCT SST
29 acidophil adenoma 10.6 IGF1 POMC SST
30 hormone producing pituitary cancer 10.6 IGF1 SST
31 sick building syndrome 10.6 LEP POMC TRPV1
32 pituitary infarct 10.5 IGF1 POMC SST
33 gallbladder disease 10.5 CCK INS SST
34 hyperinsulinemic hypoglycemia 10.5 ABCC8 INS SST
35 tuberculous epididymitis 10.5 AVP POMC
36 duodenogastric reflux 10.5 CCK SCT SST
37 lipodystrophy, familial partial, type 2 10.5 INS LEP
38 thyroid gland disease 10.5 IGF1 INS POMC
39 secondary adrenal insufficiency 10.5 AVP IGF1 INS
40 chiasmal syndrome 10.5 POMC SST
41 fetal macrosomia 10.5 IGF1 INS LEP
42 gonadal disease 10.5 IGF1 INS POMC
43 specific developmental disorder 10.5 CCK POMC TRPV1
44 biliary dyskinesia 10.5 CCK SCT
45 hyperandrogenism 10.5 IGF1 INS POMC
46 endocrine organ benign neoplasm 10.5 IGF1 POMC SST
47 chromophobe adenoma 10.5 AVP INS POMC
48 duodenal somatostatinoma 10.5 INS PPY SST
49 central nervous system germ cell tumor 10.5 AVP POMC
50 pituitary tumors 10.5 IGF1 POMC SST

Graphical network of the top 20 diseases related to Pancreas Disease:



Diseases related to Pancreas Disease

Symptoms & Phenotypes for Pancreas Disease

UMLS symptoms related to Pancreas Disease:


gastrointestinal gas, digestive system symptom, nausea and vomiting, icterus, heartburn, dyspepsia, diarrhea, constipation, abdominal pain

MGI Mouse Phenotypes related to Pancreas Disease:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.93 INS LEP POMC SLC5A2 SPINK1 ABCC8
2 adipose tissue MP:0005375 9.73 INS LEP POMC SLC5A2 TRPV1 IGF1
3 no phenotypic analysis MP:0003012 9.61 INS POMC SLC5A2 SPINK1 ABCC8 SST
4 renal/urinary system MP:0005367 9.23 INS LEP POMC SLC5A2 AVP TRPV1

Drugs & Therapeutics for Pancreas Disease

Drugs for Pancreas Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 919)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 53608-75-6
2
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 5311068 56032 68602
3
Acetaminophen Approved Phase 4,Phase 1 103-90-2 1983
4
Clonidine Approved Phase 4 4205-90-7 2803
5 Nefopam Approved, Investigational Phase 4 13669-70-0
6
Ropivacaine Approved Phase 4,Phase 2,Phase 3,Phase 1 84057-95-4 175805 71273
7
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
8
Tramadol Approved, Investigational Phase 4,Phase 2,Phase 3 27203-92-5 33741
9
Cefoperazone Approved, Investigational Phase 4 62893-19-0 44185
10
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2 55-56-1 2713 9552079
11
Meropenem Approved, Investigational Phase 4,Phase 1,Phase 2 119478-56-7 441130 64778
12
Metronidazole Approved Phase 4,Phase 1 443-48-1 4173
13
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
14 lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1 108736-35-2
15
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 83150-76-9 6400441 383414
16
Ceftazidime Approved Phase 4,Phase 1 72558-82-8, 78439-06-2 5481173
17
Tobramycin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 32986-56-4 36294 5496
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 437-38-7 3345
19
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2 2078-54-8 4943
20
Indomethacin Approved, Investigational Phase 4,Phase 3,Phase 2 53-86-1 3715
21
Diclofenac Approved, Vet_approved Phase 4,Phase 1 15307-86-5 3033
22
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2216-51-5 16666
23
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
24
Insulin Glargine Approved Phase 4,Phase 3 160337-95-1
25
Azithromycin Approved Phase 4,Phase 3,Phase 2 83905-01-5 53477736 447043 55185
26
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1 59467-70-8 4192
27
Dalteparin Approved Phase 4,Phase 3,Phase 1,Phase 2 9005-49-6
28
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 9005-49-6 46507594 772
29
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
30
Ketorolac Approved Phase 4,Phase 2,Phase 3,Phase 1 74103-06-3, 66635-83-4 3826
31
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
32 Racepinephrine Approved Phase 4,Phase 2 329-65-7
33
Aztreonam Approved Phase 4,Phase 3,Phase 2 78110-38-0 5742832 5362041
34
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 95058-81-4 60750
35
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
36
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
37
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
38
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
39
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 169590-42-5 2662
40
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2 7440-66-6 32051 23994
41
Morphine Approved, Investigational Phase 4 57-27-2 5288826
42
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
43
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
44
Remifentanil Approved Phase 4 132875-61-7 60815
45
Cilastatin Approved, Investigational Phase 4 82009-34-5 6435415 5280454
46
Imipenem Approved Phase 4 64221-86-9, 74431-23-5 104838
47
Protein C Approved Phase 4,Phase 2,Phase 1
48
Erythromycin Approved, Investigational, Vet_approved Phase 4,Phase 2 114-07-8 12560
49
Glycolic acid Approved, Investigational Phase 4 79-14-1 757
50
Thrombin Approved, Investigational Phase 4

Interventional clinical trials:

(show top 50) (show all 3347)

# Name Status NCT ID Phase Drugs
1 Effect of an Artificial Pancreas in Patients Undergoing Pancreatic Resection Unknown status NCT00661648 Phase 4
2 Dexmedetomidine Hydrochloride in the Prevention of Organ Failure Following Severe Acute Pancreatitis Unknown status NCT02691598 Phase 4 Infusion
3 Epidural Analgesia for Pancreatitis (Epipan Study) Unknown status NCT02126332 Phase 4
4 Multi-center Clinical Study of Early Antibios of Severe Acute Pancreatitis Unknown status NCT01992198 Phase 4 cefoperazone + metronidazole;Somatostatin;Meropenem
5 Comparative Study About the Impact of Two Oil Emulsions Administered Intravenously on Severe Acute Pancreatitis Unknown status NCT01376817 Phase 4 Fat emulsion with MCT, LCT, olive oil and omega 3 fatty acids;Fat emulsion with MCT and LCT
6 Prospective Random Comparing Study on EUS-guided Pseudocyst Drainage by Naso-pancreatic Tube and Stents Unknown status NCT01585662 Phase 4
7 Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy Unknown status NCT01070758 Phase 4 Lanreotide autogel
8 Evaluation of EUS-Guided 22 Gauge Core Biopsy Versus Fine-needle Aspiration for Suspected Pancreatic Neoplasms Unknown status NCT01673334 Phase 4
9 Impact of Immunonutrition on the Patients With Cystic Fibrosis Unknown status NCT02048592 Phase 4
10 Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis Unknown status NCT01044719 Phase 4 Ceftazidime;Tobramycin;Meropenem
11 Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
12 Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4 MCT/LCT and fish oil;MCT/LCT
13 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
14 RCT: Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses Completed NCT02092519 Phase 4
15 Alfentanil Versus Remifentanil in Patient-controlled Sedation During Endoscopic Retrograde Cholangiopancreatography (ERCP) Completed NCT01350037 Phase 4 alfentanil;remifentanil
16 Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy Completed NCT00526331 Phase 4
17 Imipenem Prophylaxis in Patients With Acute Pancreatitis Completed NCT02897206 Phase 4 Imipenem;Placebo
18 Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP) Completed NCT02111707 Phase 4 Rectal indomethacin 100mg one time before or after ERCP
19 Enteral Nutrition in Acute Pancreatitis Completed NCT01965873 Phase 4
20 Post ERCP Pancreatitis Prevention in Average Risk Patients Completed NCT01784445 Phase 4 Ceftazidime
21 Enzyme Suppletion in Exocrine Pancreatic Dysfunction Completed NCT01430234 Phase 4 Panzytrat 25.000 FIP-E units of Lipase
22 Sitagliptin Therapy to Improve Outcomes After Islet Autotransplant Completed NCT01186562 Phase 4 Sitagliptin;Placebo
23 Dexmedetomidine Versus Placebo in Endoscopic Retrograde Cholangiopancreatography (ERCP) Sedation Completed NCT01070680 Phase 4 Precedex;sodium chlorid 0,9%
24 Activated Protein C in Severe Acute Pancreatitis Completed NCT01017107 Phase 4 Activated protein C
25 Assess the Effect of Erythromycin on the Rate of Success in Placement of a Self-propelled Feeding Tube Completed NCT00999232 Phase 4 Erythromycin;Placebo
26 Early Enteral Nutrition for Severe Acute Pancreatitis Completed NCT00995098 Phase 4
27 Evaluation of the Digestive and Metabolic Utilisation of Dietary Protein in Patients With Chronic Pancreatitis Completed NCT00957151 Phase 4 Creon
28 Acute Pancreatitis and Acute Fluid Collections Completed NCT00786929 Phase 4 Conservative treatment
29 Nutritional and Metabolic Evaluation of a Tube Feeding Immune Enhancing Diet in ICU Patients Completed NCT00560157 Phase 4
30 Creon After Pancreatic Surgery Completed NCT00535756 Phase 4 Creon;Placebo
31 Evaluation of Pancreatic Tissue Penetration of Meronem® in the Prophylaxis of Septic Complications in Severe Pancreatitis Completed NCT00318994 Phase 4 Meropenem
32 Somatostatin, Octreotide, Pentoxyfilline in the Prevention of Post-ERCP Pancreatitis and Molecular Markers Completed NCT00222092 Phase 4
33 A Study to Determine if Antibiotics Prevent Infection in the Pancreas of Patients Where Part of the Pancreas Has Died Completed NCT00061438 Phase 4 meropenem
34 Prospective Study of Efficacy of Intra-muscular Vitamin D3 in Tropical Calcific Pancreatitis Completed NCT00956839 Phase 4 Vitamin D3 (Cholecalciferol)
35 Use of Polyethylene Glycolic Acid or Tachocomb to Prevent Pancreatic Fistula Following Distal Pancreatectomy Completed NCT01550406 Phase 4
36 Role of Octreotide in Preventing Pancreatic Fistula After Pancreaticoduodenectomy (PD) in Patients With Soft Pancreas Completed NCT01301222 Phase 4 Inj. Octreotide
37 Enteral Nutrition in the Treatment of Pancreatic Fistulas - A Prospective Study Completed NCT01025414 Phase 4 enteral nutrition;Parenteral nutrition
38 DGT Versus TPS in Patients With Initial PD Cannulation by Chance; Prospective Multi-center Study Completed NCT01744847 Phase 4
39 Electro Flo 5000 and Vest Therapy Completed NCT02277626 Phase 4
40 Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense Mutations Completed NCT03256799 Phase 4 Ivacaftor
41 A Study of the Effects of Lumacaftor/Ivacaftor on Exercise Tolerance in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation Completed NCT02875366 Phase 4 LUM/IVA;Placebo
42 The Correlations Between Early Enteral Nutrition and Intra-abdominal Pressure in Severe Acute Pancreatitis Completed NCT01507766 Phase 4 early enteral nutrition;Delayed enteral nutrition
43 Backpack Carrying in Children With Cystic Fibrosis Completed NCT02700282 Phase 4
44 A Trial of 0.025 Wire Guided Cannulation Versus Current Practice 0.035 Wire Guided Cannulation Completed NCT01408264 Phase 4
45 Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic Fibrosis Completed NCT02504827 Phase 4 Ceftazidime/avibactam
46 Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients Completed NCT02421120 Phase 4 Ceftolozane/Tazobactam
47 Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients Completed NCT02178540 Phase 4 Placebo
48 Clinical Study With an Enteral Formula With Symbiotic and DHA for Malnourished Children Completed NCT02128984 Phase 4
49 Pharmacokinetics of Piperacillin, Given as Continuous Infusion to Patients With Cystic Fibrosis Completed NCT01983787 Phase 4
50 Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy Completed NCT01882400 Phase 4 Bisphosphonate treatment

Search NIH Clinical Center for Pancreas Disease

Genetic Tests for Pancreas Disease

Genetic tests related to Pancreas Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Pancreas 28

Anatomical Context for Pancreas Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Pancreas Disease:

18
The Pancreas

MalaCards organs/tissues related to Pancreas Disease:

38
Pancreas, Lung, Testes, Liver, T Cells, Breast, Colon

Publications for Pancreas Disease

Articles related to Pancreas Disease:

(show top 50) (show all 72)
# Title Authors Year
1
Use of Salmon Cardiac Primary Cultures (SCPCs) of different genotypes for comparative kinetics of mx expression, viral load and ultrastructure pathology, after infection with Salmon Pancreas Disease Virus (SPDV). ( 29102629 )
2018
2
Non-alcoholic fatty pancreas disease. ( 28069746 )
2017
3
Protein kinase STK25 aggravates the severity of non-alcoholic fatty pancreas disease in mice. ( 28442507 )
2017
4
Polycystic Pancreas Disease. ( 29287005 )
2017
5
Impact of non-alcoholic fatty pancreas disease on glucose metabolism. ( 28371475 )
2017
6
The epidemiological and economic effects from systematic depopulation of Norwegian marine salmon farms infected with pancreas disease virus. ( 27664454 )
2016
7
Exploring the metabolic syndrome: Nonalcoholic fatty pancreas disease. ( 27678349 )
2016
8
Ballan wrasse (Labrus bergylta Ascanius) is not susceptible to pancreas disease caused by salmonid alphavirus subtype 2 and 3. ( 27859355 )
2016
9
Vaccination against pancreas disease in Atlantic salmon, Salmo salar L., reduces shedding of salmonid alphavirus. ( 27496170 )
2016
10
Experimental Piscine orthoreovirus infection mediates protection against pancreas disease in Atlantic salmon (Salmo salar). ( 27769313 )
2016
11
The epidemiology of pancreas disease in salmonid aquaculture: a summary of the current state of knowledge. ( 27136332 )
2016
12
Xenopus as a Model for GI/Pancreas Disease. ( 26236566 )
2015
13
Mapping and validation of a major QTL affecting resistance to pancreas disease (salmonid alphavirus) in Atlantic salmon (Salmo salar). ( 25990876 )
2015
14
Comparison of transcriptomic responses to pancreas disease (PD) and heart and skeletal muscle inflammation (HSMI) in heart of Atlantic salmon (Salmo salar L). ( 26232631 )
2015
15
Nonalcoholic fatty pancreas disease and Nonalcoholic fatty liver disease: more than ectopic fat. ( 26201937 )
2015
16
Prevalence of Non-Alcoholic Fatty Pancreas Disease (NAFPD) and its risk factors among adult medical check-up patients in a private hospital: a large cross sectional study. ( 26652175 )
2015
17
The economic benefits of disease triggered early harvest: A case study of pancreas disease in farmed Atlantic salmon from Norway. ( 26297077 )
2015
18
Space-time modelling of the spread of pancreas disease (PD) within and between Norwegian marine salmonid farms. ( 26104836 )
2015
19
An experimental means of transmitting pancreas disease in Atlantic salmon Salmo salar L. fry in freshwater. ( 25297529 )
2014
20
Serum enolase: a non-destructive biomarker of white skeletal myopathy during pancreas disease (PD) in Atlantic salmon Salmo salar L. ( 25168106 )
2014
21
Clinical signature and pathogenetic factors of diabetes associated with pancreas disease (T3cDM): a prospective observational study in surgical patients. ( 24974302 )
2014
22
Enigmatic ectopic fat: prevalence of nonalcoholic fatty pancreas disease and its associated factors in a Chinese population. ( 24572250 )
2014
23
Clinical manifestations of pancreas disease outbreaks in Norwegian marine salmon farming - variations due to salmonid alphavirus subtype. ( 24661057 )
2014
24
Non-alcoholic fatty pancreas disease pathogenesis: a role for developmental programming and altered circadian rhythms. ( 24657938 )
2014
25
Cross-sectional study to investigate the presence of salmon pancreas disease virus in wild and feral fish populations in 10A lakes, Los Lagos Region, Chile. ( 24382013 )
2014
26
Transmission dynamics of pancreas disease (PD) in a Norwegian fjord: aspects of water transport, contact networks and infection pressure among salmon farms. ( 25254274 )
2014
27
The association between nonalcoholic fatty pancreas disease and diabetes. ( 23671610 )
2013
28
Comparative cardiac pathological changes of Atlantic salmon (Salmo salar L.) affected with heart and skeletal muscle inflammation (HSMI), cardiomyopathy syndrome (CMS) and pancreas disease (PD). ( 23200434 )
2013
29
The serum proteome of Atlantic salmon, Salmo salar, during pancreas disease (PD) following infection with salmonid alphavirus subtype 3 (SAV3). ( 24145143 )
2013
30
Seasonal increase in sea temperature triggers pancreas disease outbreaks in Norwegian salmon farms. ( 23980568 )
2013
31
Estimation of the reproduction number of salmon pancreas disease virus subtype 3 in homogeneously mixed populations of Norwegian farmed Atlantic salmon. ( 23810623 )
2013
32
Transmission dynamics of pancreas disease (PD) in a Norwegian fjord: aspects of water transport, contact networks and infection pressure among salmon farms. ( 23452114 )
2013
33
Mortality related to pancreas disease in Norwegian farmed salmonid fish, Salmo salar L. and Oncorhynchus mykiss (Walbaum). ( 23311767 )
2013
34
Immune parameters correlating with reduced susceptibility to pancreas disease in experimentally challenged Atlantic salmon (Salmo salar). ( 23306092 )
2013
35
Risk map and spatial determinants of pancreas disease in the marine phase of Norwegian Atlantic salmon farming sites. ( 23006469 )
2012
36
Quality of raw and smoked fillets from clinically healthy Atlantic salmon, Salmo salar L., following an outbreak of pancreas disease (PD). ( 22924617 )
2012
37
Detection of salmon pancreas disease virus in the faeces and mucus of Atlantic salmon, Salmo salar L., by real-time RT-PCR and cell culture following experimental challenge. ( 22924477 )
2012
38
Cohort study of effect of vaccination on pancreas disease in Norwegian salmon aquaculture. ( 23209075 )
2012
39
Spleen-derived interleukin-10 downregulates the severity of high-fat diet-induced non-alcoholic fatty pancreas disease. ( 23285260 )
2012
40
Formulations combining CpG containing oliogonucleotides and poly I:C enhance the magnitude of immune responses and protection against pancreas disease in Atlantic salmon. ( 21527278 )
2011
41
Salmonid alphavirus (SAV) and pancreas disease (PD) in Atlantic salmon, Salmo salar L., in freshwater and seawater sites in Norway from 2006 to 2008. ( 20158578 )
2010
42
Maternal obesity programmes offspring development of non-alcoholic fatty pancreas disease. ( 20170634 )
2010
43
Stochastic modelling of direct costs of pancreas disease (PD) in Norwegian farmed Atlantic salmon (Salmo salar L.). ( 19931201 )
2010
44
A stochastic model for the assessment of the transmission pathways of heart and skeleton muscle inflammation, pancreas disease and infectious salmon anaemia in marine fish farms in Norway. ( 19811843 )
2010
45
Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease. ( 20871475 )
2010
46
Pancreas disease (PD) in sea-reared Atlantic salmon, Salmo salar L., in Norway; a prospective, longitudinal study of disease development and agreement between diagnostic test results. ( 20609035 )
2010
47
Detection of salmonid alphavirus RNA in wild marine fish: implications for the origins of salmon pancreas disease in aquaculture. ( 21133318 )
2010
48
A Mouse Model of Metabolic Syndrome: Insulin Resistance, Fatty Liver and Non-Alcoholic Fatty Pancreas Disease (NAFPD) in C57BL/6 Mice Fed a High Fat Diet. ( 20490316 )
2010
49
Risk factors for pancreas disease (PD) outbreaks in farmed Atlantic salmon and rainbow trout in Norway during 2003-2007. ( 19419787 )
2009
50
Integration of hydrodynamics into a statistical model on the spread of pancreas disease (PD) in salmon farming. ( 20183963 )
2009

Variations for Pancreas Disease

Expression for Pancreas Disease

Search GEO for disease gene expression data for Pancreas Disease.

Pathways for Pancreas Disease

GO Terms for Pancreas Disease

Cellular components related to Pancreas Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.77 CCK CELA1 CELA3B GCG IGF1 INS
2 extracellular region GO:0005576 9.5 AVP CCK CELA1 DPP4 GCG IGF1

Biological processes related to Pancreas Disease according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.93 CCK DPP4 IGF1 INS LEP
2 G-protein coupled receptor signaling pathway GO:0007186 9.76 AVP CCK GCG INS POMC PPY
3 glucose homeostasis GO:0042593 9.74 INS LEP POMC
4 positive regulation of MAPK cascade GO:0043410 9.72 IGF1 INS LEP
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.67 CCK IGF1 INS
6 cell-cell signaling GO:0007267 9.65 AVP INS POMC PPY SST
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.61 IGF1 INS LEP
8 negative regulation of release of cytochrome c from mitochondria GO:0090201 9.58 AVP IGF1
9 digestion GO:0007586 9.58 PPY PRSS1 SST
10 positive regulation of glycogen biosynthetic process GO:0045725 9.56 IGF1 INS
11 response to heat GO:0009408 9.54 IGF1 SST TRPV1
12 response to pH GO:0009268 9.52 ABCC8 TRPV1
13 positive regulation of insulin receptor signaling pathway GO:0046628 9.51 INS LEP
14 regulation of appetite GO:0032098 9.48 POMC PPY
15 negative regulation of appetite GO:0032099 9.46 CCK LEP
16 bone mineralization involved in bone maturation GO:0035630 9.32 IGF1 LEP
17 regulation of receptor activity GO:0010469 9.32 AVP CCK GCG IGF1 INS LEP
18 regulation of insulin secretion GO:0050796 9.26 ABCC8 DPP4 GCG LEP

Molecular functions related to Pancreas Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptidase activity GO:0008233 9.8 CELA1 CELA3B DPP4 PRSS1 PRSS58
2 receptor binding GO:0005102 9.73 AVP DPP4 GCG LEP POMC PPY
3 serine-type endopeptidase activity GO:0004252 9.72 CELA1 CELA3B DPP4 PRSS1 PRSS58
4 serine-type peptidase activity GO:0008236 9.55 CELA1 CELA3B DPP4 PRSS1 PRSS58
5 insulin-like growth factor receptor binding GO:0005159 9.43 IGF1 INS
6 glucose:sodium symporter activity GO:0005412 9.37 SLC5A2 SLC5A4
7 hormone activity GO:0005179 9.32 AVP CCK GCG IGF1 INS LEP
8 neuropeptide hormone activity GO:0005184 9.26 AVP CCK POMC PPY

Sources for Pancreas Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....